The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Sports
  • Event

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • MoMojo Records announces new album from Mitch Woods
  • From Broken to Soaring Week 40
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Appliance EMT Launches June "Summer Rescue" Promotion
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
  • Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
  • K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
  • Individual Entrepreneur of Annville, PA, Acquires Mosquito Joe of Lancaster, PA
  • Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
  • PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
  • Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
  • The Problem With AI Isn't Compute. It's Memory
  • Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
  • Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
  • Wine School of Philadelphia Celebrates 25 Years With Intensive Summer Program
  • Greensburg Pennsylvania Martial Arts School Racks Up BJJ Wins
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
  • New analysis reveals second job workers keep just 80p in every pound they earn
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • American Ethiopian Public Affairs Committee (AEPAC) Applauds Pennsylvania House Recognition of Adwa VictoryDay
  • A Foundational Claim in Human Secrecy Goes Public
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Fourth Annual Free Training Day Mid-Atlantic Returns Sept. 19, 2026
  • Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 135
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach - 108
  • All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
  • Edwards & Virginia Business Systems Announces Leadership Appointments
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • T. Jones Group Named Finalist Across Multiple Categories at the 2026 Georgie Awards
  • Ed, Edd n Eddy, Resident Evil, Anime Voice Actors Augment FAN EXPO Philadelphia Lineup
  • SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility
  • The Simplest Small Business You're Probably Not Thinking About
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope

Similar on PennZone

  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us